Esperion Therapeutics, Inc. Overview
Pro stress-test →Esperion Therapeutics is a commercial-stage biopharmaceutical company focused on FDA-approved oral, once-daily, non-statin medicines for patients at risk for cardiovascular disease with elevated LDL-C cholesterol. The company announced its Vision 2040 Growth Strategy in January 2026, a bold roadmap to transform Esperion into a multi-product, sustainable, innovation-driven global pharmaceutical company.
Strategic Profile
Pro stress-test →Over the past twelve months, Esperion has evolved from a single bempedoic acid franchise story to a more articulated commercial-stage biotech case with three concurrent drivers: U.S. commercial growth, international partner monetization, and portfolio expansion through the acquisition of Corstasis Therapeutics. The company leverages deep expertise in ACLY biology, a critical metabolic enzyme positioned at the intersection of nutrient catabolism and cholesterol and fatty acid biosynthesis.
Competitive Landscape
Pro stress-test →Esperion competes in the cholesterol-lowering and cardiometabolic therapeutic space against established statins and newer non-statin players. Direct competitors include Amgen's inclisiran (LEQVIO), a PCSK9-inhibiting siRNA therapy, and Novartis/Leqvio (inclisiran) as alternatives for LDL-C reduction. Biopharma competitors developing ACLY inhibitors and dual-action cardiovascular agents also pose competitive threats. Esperion's differentiation lies in its established NEXLETOL/NEXLIZET franchise, recent Corstasis acquisition adding heart failure indication, and extended patent protection through strategic generic agreements.
Industry Context
Esperion Therapeutics, Inc. operates in Cardiometabolic disease therapeutics.
Key facts
Founded: 2008 · Headquarters: Ann Arbor, Michigan · Employees: Approximately 500-600 (as of 2026-07-24; not publicly disclosed in recent filings) · Revenue: $403.1 million (full-year 2025); Q1 2026: $80.1 million · Market cap: Approximately $500M-$600M (as of July 2026; estimate based on $3.19 analyst target)